Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS: A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [24]
In the citing paper
“Large observational studies or head-to-head RCTs show similar rates of gastrointestinal and non-gastrointestinal major bleeding for single antiplatelet therapy (SAPT) with low-dose ASA or a P2Y 12 inhibitor (clopidogrel or ticagrelor).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Regarding CV safety, the composite of MI, stroke, CV death, CHD, and acute limb ischaemia was similar between pantoprazole and placebo, as was the rate of new-onset diabetes.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Thus, gastrointestinal mucosal bleeding appears to be due to pre-existing mucosal lesions associated with defective primary haemostasis secondary to platelet inhibition, rather than with a specific antiplatelet drug.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Combined antithrombotic drugs, while effective, increase major bleeding risk.337,338”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Research works printed but not linked: 1
- Feres F, 2013, JAMA, 310, 2510
Cited by
Items 901–1,000 of 1,001
Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention
Hideo‐Kajita, A., Rogers, T., Buchanan, K. D., Iantorno, M., Gajanana, D., Ozaki, Y., Dan, K., Kolm, P., Brathwaite, E. J., Beyene, S., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.01.031 · Cited by 8
Gallone, G., D’Ascenzo, F., Conrotto, F., Costa, F., Capodanno, D., Muscoli, S., Chieffo, A., Imori, Y., Pennacchi, M., Quadri, G., et al. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28972 · Cited by 8
“patients at high ischemic risk exclusively (as defined by a DAPT score ≥2), while associating with increased bleeding among patients at low ischemic risk (DAPT score <2).(32,33)”
BackgroundA systematic review of the studies that evaluate the performance of the DAPT score
Kwok, C. S., Wong, C. W., Nagaraja, V., & Mamas, M. A. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13591 · Cited by 8
Dual antiplatelet therapy after percutaneous coronary intervention: Personalize the duration
Howard, T. M., & Khot, U. N. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20113 · Cited by 8
“The fi rst and largest study to investigate this question 18 found that in patients who completed 12 months of DAPT after PCI without suffering an ischemic or bleeding event, continuing DAPT for 18 additional months reduced myocardial infarction and stent thrombosis rates but increased major…”
BackgroundGamal, A. S., Hara, H., Tomaniak, M., Lunardi, M., Gao, C., Ono, M., Kawashima, H., Jüni, P., Vranckx, P., Windecker, S., et al. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuab033 · Cited by 8
“Several attempts have been made to investigate the need and optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), either in an elective or acute setting.(1) With specific regard to acute coronary syndrome (ACS), dedicated trials were designed to analyse the benefits of di…”
MethodSelf-citationNakagawa, Y., Kadota, K., Nakao, K., Shite, J., Yokoi, H., Kozuma, K., Tanabe, K., Akasaka, T., Shinke, T., Ueno, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-21-1004 · Cited by 8
Luo, L., Wang, S., Tang, K., Yang, X., Wu, J., Wang, D., Xu, L., Feng, T., Li, D., Ran, J., et al. (2022) · Medicine · doi:10.1097/md.0000000000031158 · Cited by 8
“merged DAPT 2014([36]) Not sure Open-label Center allocation Basically complete*, ITT No Not sure DES-LATE 2014([37]) Computer Open-label Not sure Basically complete*, ITT No Not sure OPTIDUAL 2016([38]) Computer Open-label Interactive-response computer system Basically complete*, ITT No Not sure ARCTIC 2014([39]) Com…”
BackgroundLahu, S., Scalamogna, M., Ndrepepa, G., Menichelli, M., Valina, C. M., Hemetsberger, R., Witzenbichler, B., Bernlochner, I., Joner, M., Xhepa, E., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.027257 · Cited by 8
The year in cardiology 2014: acute coronary syndromes
de Werf, F. V., & Crea, F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu488 · Cited by 8
Kereiakes, D. J., Cannon, L., Dauber, I. M., Ball, M. W., Bertolet, B. D., Foster, M. C., Nersesov, A., Underwood, P. L., Allocco, D. J., & Dawkins, K. D. (2015) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.25877 · Cited by 8
“Although this observation suggests that both thinner struts as well as drug elution may be contributory to the clinical benefit observed with PtCr-PES stent use in SVs, The differential compliance with dual antiplatelet therapy (less in the BMS cohort) at 1 and 2 years follow-up may have also influenced the relative i…”
BackgroundSelf-citationAlmanac 2015: coronary artery disease
Shavelle, D. M. (2016) · Heart · doi:10.1136/heartjnl-2015-307761 · Cited by 9
Dadjou, Y., Safavi, S., & Kojuri, J. (2016) · Medicine · doi:10.1097/md.0000000000003663 · Cited by 8
Koh, J., Park, Y., Tantry, U. S., Ahn, J., Kang, M. G., Kim, K., Jang, J. Y., Park, H. W., Park, J. R., Hwang, S., et al. (2016) · Platelets · doi:10.1080/09537104.2016.1206197 · Cited by 8
A clinical risk score to identify patients at high risk of very late stent thrombosis
Godschalk, T. C., Gimbel, M. E., Nolet, W. W., van Kessel, D. J., Amoroso, G., Dewilde, W. J. M., Wykrzykowska, J. J., Janssen, P. W. A., Bergmeijer, T. O., Kelder, J. C., et al. (2018) · Journal of Interventional Cardiology · doi:10.1111/joic.12494 · Cited by 8
“In 2014, the Dual Antiplatelet Therapy (DAPT) study investigated the effect of prolonged DAPT on atherothrombotic and bleeding events, by comparing 12 months of treatment after DES implantation to 30 months of treatment.(16) Continuation of DAPT up to 30 months after stent implantation significantly reduced the risk o…”
BackgroundPrescribing Patterns of Oral Antiplatelets in Wales: Evolving Trends From 2005 to 2016
Protty, M. B., Wilkins, S. J., Hoskins, H. C., Dawood, B. B., & Hayes, J. (2018) · Future Cardiology · doi:10.2217/fca-2018-0003 · Cited by 8
Welsh, R. C., Peterson, E. D., Caterina, R. D., Bode, C., Gersh, B. J., & Eikelboom, J. W. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.09.006 · Cited by 10
Jin, C. D., Kim, M. H., Guo, L. Z., Jin, E., Shin, E., Ann, S. H., Cho, Y., Park, J. S., Kim, S., & Lee, M. S. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.01.058 · Cited by 8
Garg, A., Rout, A., Sharma, A., Sargsyan, D., Beavers, T., Tantry, U. S., Gurbel, P. A., Rao, S. V., Kostis, J. B., & Cohen, M. C. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.03.018 · Cited by 8
Wang, H., Cai, Z., Yin, D., Song, W., Feng, L., Gao, R.-L., Yang, Y., & Dou, K. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.586491 · Cited by 8
“A large body of evidence has described that treatment with DAPT over 12 months enabled reduction of the risk of either ST or atherothrombotic events related to an area remote from the stent (4, 5, 23, 24).”
BackgroundGawinski, L. P., Engelseth, P., & Kozłowski, R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179103 · Cited by 10
“Undoubtedly, the use of dual antiplatelet therapy (DAPT) reduces the number of ischemic episodes in patients undergoing coronary stent implantation, but at the same time increases the risk of bleeding [58].”
BackgroundLin, Y., Cai, Z., Dong, S., Liu, H., Pang, X., Chen, Q., Yuan, J., & Geng, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.992376 · Cited by 8
“Among of these studies, aspirin and clopidogrel were used in five studies (Park et al., 2010; Collet et al., 2014; Lee et al., 2014; Mauri et al., 2014; Helft et al., 2016), aspirin and ticagrelor 90 mg b.”
BackgroundMethodManagement of the patient with an acute coronary syndrome using oral anticoagulation
Vos, G. J. A., Bennaghmouch, N., Qaderdan, K., & ten Berg, J. M. (2015) · Netherlands Heart Journal · doi:10.1007/s12471-015-0727-0 · Cited by 8
Collet, J., Silvain, J., Kernéis, M., Cuisset, T., Meneveau, N. F., Boueri, Z., Barthélémy, O., Rangé, G., Cayla, G., BELLE, E. V., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22512 · Cited by 8
Bardají, A., Leal, M., Arrarte, V., García–Moll, X., de Isla, L. P., & Bueno, H. (2016) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12237 · Cited by 8
“A number of trials and meta-analyses also suggest that prolonged DAPT reduces the incidence of ischemic events compared with standard duration, although at the expense of increased potential for bleeding [7-9].”
Arbel, Y., Bennell, M. C., Goodman, S. G., & Wijeysundera, H. C. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.10.004 · Cited by 8
Percutaneous Coronary Intervention in the Elderly: Are Drug-coated Balloons the Future?
Merinopoulos, I., Gunawardena, T., Wickramarachchi, U., Ryding, A., Eccleshall, S., & Vassiliou, V. S. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x14666171226144120 · Cited by 8
“Despite the associated increase in bleeding risk, the majority of patients tend to tolerate antiplatelet therapy well in trial data [16, 17].”
BackgroundWang, Z., Liu, Z., Wang, W., Fu, Y., Chen, W., Li, W., Zhang, X., Tang, Y., & Zhou, Z. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-018-0036-2 · Cited by 9
P2Y12 inhibitors: do they increase cancer risk?
Fierro, J. J., Cave, B. E., & Khouzam, R. N. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.90 · Cited by 8
“Regarding prasugrel, a post-hoc investigation of the TRILOGY-ACS trial to assess participants’ cancer history found that the cancer incidence was low overall and similar among patients on prasugrel and clopidogrel (1.8% versus 1.7%, P=0.79) (11).”
InfluentialPractical experience with ticagrelor: an Australian and New Zealand perspective
Harding, S. A., van Gaal, W. J., Schrale, R. G., Gunasekara, A. P., Amerena, J. V., Mussap, C., & Aylward, P. E. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1058247 · Cited by 8
Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma
Gurbel, P. A., & Tantry, U. S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv573 · Cited by 8
You, S. C., & Krumholz, H. M. (2022) · Circulation · doi:10.1161/circulationaha.121.057931 · Cited by 10
Polymers for Biomedical Applications: the Quest for Treating Cardiovascular Diseases
Daele, L. V., Vlierberghe, S. V., & Dubruel, P. (2025) · Advanced Materials · doi:10.1002/adma.202514833 · Cited by 8
Dual antiplatelet therapy escalation and de-escalation
Greco, A., Leo, G. D., Finocchiaro, S., Imbesi, A., & Capodanno, D. (2026) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaf173 · Cited by 10
Gorog, D. A., ten Berg, J. M., Campo, G. C., Geisler, T., Gigante, B., Grove, E. L., Halvorsen, S., Huber, K., Jeong, Y., Lip, G. Y. H., et al. (2026) · EuroIntervention · doi:10.4244/eij-e-26-00003 · Cited by 8
Garratt, K. N. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.09.001 · Cited by 8
Self-citation2014 Update on Interventional Cardiology
Hernández, F., Hernández, J. M. D. L. T., Cuevas, J. R. R., del Blanco, B. G., Martínez‐Sellés, M., & Trillo, R. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.12.009 · Cited by 7
Kinnaird, T. D., Butt, M., Abdul, F. B., Yazji, K., Hailan, A., Gallagher, S., Ossei‐Gerning, N., Chase, A. J., Choudhury, A., Smith, D. A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157812 · Cited by 7
Völz, S., Angerås, O., Odenstedt, J., Ioanes, D., Haraldsson, I., Dworeck, C., Redfors, B., Råmunddal, T., Albertsson, P., Pétursson, P., et al. (2018) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.27655 · Cited by 7
Gutierrez, J. A., Bhatt, D. L., Banerjee, S., Glorioso, T. J., Josey, K., Swaminathan, R. V., Maddox, T. M., Armstrong, E. J., Duvernoy, C. S., Waldo, S. W., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.04.004 · Cited by 7
Chen, J., Liu, S., Ruan, Z., Wang, K., Xi, X., & Mao, J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101220 · Cited by 8
Antithrombotic Therapy in Patients with Chronic Coronary Syndromes
Mazzone, P. M., Spagnolo, M., & Capodanno, D. (2024) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2024.06.004 · Cited by 7
Gitto, M., Gilhooley, S., Smith, K. F., Vogel, B., Sartori, S., Bay, B., Krishnan, P., Sweeny, J. M., Oliva, A., Moreno, P., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae399 · Cited by 7
Marschall, A., Rivero, F., del Val, D., Bastante, T., Soberon, E. L., Sánchez, I. G., Velasco, E. B., Alfonso, F., Hernández, J. M. D. L. T., & Sánchez, D. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041194 · Cited by 7
“…therapy after drug-eluting stents (DAPT) and the long-term use of ticagrelor in patients with prior myocardial infarction (PEGASUS-TIMI 54) trials, extending DAPT beyond 12 months should be considered for patients with high ischemic risk provided they are not at high risk of bleeding [53,55].”
Song, P. S., Hahn, J., Kim, D., Song, Y. B., Choi, S., Choi, J., Ryu, D. R., Hur, S., Jeong, J., Park, H. S., et al. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.06.014 · Cited by 7
“The results of our study somewhat contradict those obtained in the Swedish Web-System for Enhancement and Development of EvidenceBased Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) study and DAPT trial [15,16].”
ResultNatarajan, P., Jaffer, F. A., & Sabatine, M. S. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4483-0_3 · Cited by 7
Nakamura, M., Muramatsu, T., Yokoi, H., Okada, H., Ochiai, M., Suwa, S., Hozawa, H., Kawai, K., Awata, M., Mukawa, H., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.023 · Cited by 7
Bömicke, T., Valina, C. M., Stratz, C., Amann, M., Neumann, F., & Hochholzer, W. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-02-0122 · Cited by 7
“However, recent trials have demonstrated that patients might stay at an increased risk for ischaemic events even more than 12 months following coronary stent implantation and that continuation of DAPT longer than 12 months can reduce this risk (13, 14).”
BackgroundInfluentialANTITHROMBOTIC THERAPY IN ELDERLY AND SENILE AGE: AN EXPERT CONSENSUS
Tkacheva, O. N., Рунихина, Н. К., VOROBIOVA, N., Komarov, A. L., Kotovskaya, Y. V., Панченко, Е. П., Владимировна, П. Е., Frolova, E. V., & Yavelov, I. S. (2017) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2017-3-4-33 · Cited by 7
Analysis of the COMPARE-AMI trial: First report of long-term safety of CD133+ cells
Haddad, K., Potter, B. J., Matteau, A., Reeves, F., Leclerc, G., Rivard, A., Gobeil, F., Roy, D., Noiseux, N., & Mansour, S. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.06.004 · Cited by 7
Wang, H., Cai, Z., Yin, D., Yang, Y., Song, W., & Dou, K.-F. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.11.043 · Cited by 7
Li, X., Qiu, M., Na, K., Li, Y., Ma, S., Qi, Z., Li, J., Li, Y., & Han, Y. (2021) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29591 · Cited by 7
“events in patients with ACS with a high-risk of ischemia, more powerful antiplatelet strategies, including a prolonged treatment duration and a more potent P2Y12 inhibitor, may significantly reduce the formation of systemic atherosclerotic thrombosis and the occurrence of recurrent ischemic events.(6,20) Our results i…”
ResultP2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor
Kim, J., Jang, W. J., Lee, W. S., Choi, K. H., Lee, J. M., Park, T. K., Yang, J. H., Choi, J., Song, Y. B., Choi, S., et al. (2021) · Heart · doi:10.1136/heartjnl-2020-318821 · Cited by 7
Christensen, D. M., Schjerning, A.-M., Sindet‐Pedersen, C., Lamberts, M., Olesen, J. B., Barcella, C. A., Torp-Pedersen, C. T., Gislason, G., & Strange, J. E. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.11.018 · Cited by 7
Monitoring of Antiplatelet Therapy
Tantry, U. S., Myat, A., & Gurbel, P. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_45 · Cited by 7
Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
Jourdi, G., Marquis‐Gravel, G., Martin, A., Lordkipanidzé, M., Godiér, A., & Gaussem, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.878416 · Cited by 7
“Importantly, the risk of stent thrombosis and myocardial infarction was comparable between both groups during the 3 months after discontinuation of thienopyridine treatment (Mauri et al., 2014).”
BackgroundPlatelet Reactivity: Is There a Role to Switch?
Aradi, D., Merkely, B. P., & Komócsi, A. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.08.008 · Cited by 7
Alfredsson, J., & Roe, M. T. (2015) · Drug Safety · doi:10.1007/s40264-015-0286-8 · Cited by 7
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events
Myat, A., Tantry, U. S., Kubica, J., & Gurbel, P. A. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1247693 · Cited by 7
An Updated Protocol for Evaluating Chest Pain and Managing Acute Coronary Syndromes
Kelly, C. R., Kirtane, A. J., Stant, J. A., Stone, G. W., Minutello, R. M., Wong, S. C., Manuzon, H., Gerow-Smith, R., Kelley, N., & Rabbani, L. E. (2017) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000098 · Cited by 7
Medikamentenfreisetzende Koronarstents/-scaffolds und medikamentenbeschichtete Ballonkatheter
NEF, H. M., Abdel‐Wahab, M., Achenbach, S. S., Joner, M., Levenson, B., Mehilli, J., Möllmann, H., Thiele, H., Zahn, R., Zeus, T., et al. (2017) · Der Kardiologe · doi:10.1007/s12181-017-0202-9 · Cited by 8
Bian, L., Qiu, M., Li, Y., Xu, X., Li, J., Ma, S., Qi, Z., & Han, Y. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28736 · Cited by 7
“Given the poor long-term prognosis due to recurrent ischemic events in ACS patients particularly with high-risk of ischemia, continuous platelet inhibition may further reduce the formation of systemic atherosclerotic thrombosis and the occurrence of recurrent ischemic events theoretically.(20,21) In the present study,…”
BackgroundAntithrombotic Treatment After Coronary Intervention: Agreement and Controversy
Camarero, T. G., & Hernández, J. M. D. L. T. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.25.2 · Cited by 7
Liu, M., Zhuang, X., Chen, X., Zhang, S., Yang, D.-Y. D., Zhong, X., Xiong, Z., Lin, Y., Zhou, H., Fan, Y., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13324 · Cited by 7
Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention
Alkhalil, M., Džavík, V., Bhatt, D. L., Mehran, R., & Mehta, S. R. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01645-0 · Cited by 7
Luca, L. D., Rubboli, A., Lettino, M., Tubaro, M., Leonardi, S., Casella, G., Valente, S., Rossini, R., Sciahbasi, A., Natale, E., et al. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartj/suac020 · Cited by 8
Fernando, H., McFadyen, J. D., Wang, X., Shaw, J. A., Stub, D. A., & Peter, K. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.854813 · Cited by 7
Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes
Bonanad, C., Claramunt, F. E., García‐Blas, S., Ayesta, A., Díez‐Villanueva, P., Pérez-Rivera, J.-Á., Ferreiro, J. L., Cànoves, J., López-Fornás, F. J., Ariza‐Solé, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113008 · Cited by 7
“Consistently with these results, the DAPT and PEGASUS-TIMI 54 studies showed that prolonged treatment with DAPT increased the risk of bleeding across all age subgroups [13,37].”
ResultAdherence of ticagrelOr in real world patients with aCute coronary syndrome: The AD-HOC study
Fiocca, L., Rossini, R., Carioli, G., Carobbio, A., Piazza, I., Collaku, E., Giubilato, S., Amico, F., Molfese, M., Benedictis, M. D., et al. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101092 · Cited by 7
P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention
Zhou, X., Angiolillo, D. J., & Ortega‐Paz, L. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9100340 · Cited by 7
Carciotto, G., Costa, F., Garcia-Ruiz, V., Galli, M., Soraci, E., Magliarditi, A., Teresi, L., Nasso, E., Carerj, S., Bella, G. D., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12227144 · Cited by 7
“These patients are considered to be at double-sided risk: high risk for bleeding, and high risk for recurrent ischemic or thrombotic events.”
BackgroundMethodInfluentialWasfy, J. H., Kennedy, K. F., Chen, J., Ferris, T. G. G., Maddox, T. M., & Yeh, R. W. (2015) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2015.08.010 · Cited by 7
“The publication of the DAPT trial may encourage longer courses of DAPT after PCI, which will heighten the relevance of this clinical situation (25).”
MethodSelf-citationAsher, E., Abu‐Much, A., Goldenberg, I., Segev, A., Sabbag, A., Mazin, I., Shlezinger, M., Atar, S., Zahger, D., Pollak, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157437 · Cited by 8
Russo, J. J., Goodman, S. G., Bagai, A., Déry, J., Tan, M., Fisher, H. N., Zhang, X., Zhu, Y. E., Welsh, R. C., Siega, A. D., et al. (2016) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcw051 · Cited by 7
“OAC on discharge, n (%) 25 (24) 31 (22) 38 (15) 183 (12) <0.”
Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond
Pareek, M., & Bhatt, D. L. (2018) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux042 · Cited by 7
Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome
Mazlan‐Kepli, W., Dawson, J., Berry, C., & Walters, J. (2018) · Heart · doi:10.1136/heartjnl-2018-313148 · Cited by 7
An update on the use of anticoagulant therapy in ST-segment elevation myocardial infarction
van Gameren, M., Lemmert, M. E., Wilschut, J., Daemen, J., de Jaegere, P. P. T., Zijlstra, F., Mieghem, N. M. V., & Diletti, R. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1512583 · Cited by 7
“Bothprolonged [47,48] and shorteneduse (baseduponplatelet function testing [49] or CYP2C19 genotyping [50]) of antiplatelet agents is the subject of many pending trials in the general STEMI population but also in patients with a specific risk profile.”
BackgroundTerrier, J. E., Daali, Y., Fontana, P., Csajka, C., & Reny, J. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00792-y · Cited by 8
Mishra, A., Singh, M., Acker, W. W., Kamboj, S., Sporn, D., Stapleton, D. D., & Kaluski, E. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000697 · Cited by 7
Schmidt, A. C. S., Steg, P. G., Yeh, R. W., Kereiakes, D. J., Tanguay, J., Hsieh, W.-H., Massaro, J. M., Mauri, L., & Cutlip, D. E. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.09.006 · Cited by 7
Self-citationDirect-acting Anticoagulants in Chronic Coronary Syndromes
Sorbets, E., & Steg, P. G. (2020) · European Cardiology Review · doi:10.15420/ecr.2018.24.2 · Cited by 7
Self-citationHo, A., Egolum, U. O., Parker, S., Dimmel, J., Hawkins, A., & Ling, H. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00947-x · Cited by 7
Kawashima, H., Tomaniak, M., Ono, M., Wang, R., Hara, H., Gao, C., Takahashi, K., Sharif, F., Thury, A. Á., Suryapranata, H., et al. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.09.057 · Cited by 7
Self-citationClinical Trials in the 21st Century — Promising Avenues for Better Studies
Pencina, M. J., & Thompson, B. (2022) · NEJM Evidence · doi:10.1056/evidctw2200060 · Cited by 7
The Shifting Pendulum for DAPT After PCI
Sharma, S. K., & Baber, U. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.015 · Cited by 7
“Overall, findings from these studies have shown that prolonging DAPT significantly reduces coronary thrombotic events, albeit at an excess risk of nonfatal bleeding, with increased rates of noncardiac and all-cause mortality (4,6).”
The DAPT Score Uncouples Bleeding and Ischemic Risk…Again
Yeh, R. W., & Mihatov, N. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.01.211 · Cited by 7
Self-citationReal World Data as Trial End Points: Off and Running With a Long Way to Go
Konstam, M. A. (2020) · Circulation · doi:10.1161/circulationaha.120.048019 · Cited by 7
Dual Antiplatelet Therapy Duration Following Percutaneous Coronary Intervention: Time for a Change
Kereiakes, D. J. (2025) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2024.102510 · Cited by 7
“16 Recent analyses involving longer-term platelet inhibition in subjects with coronary disease suggest that P2Y12i monotherapy (either ticagrelor or clopidogrel) provides greater safety and effectiveness than aspirin.”
Self-citationA history of the development of dual antiplatelet therapy for coronary artery disease
Coughlan, J. J., Durand, R., Birrane, J. P., Blackburne, B., Kastrati, A., & Byrne, R. A. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.011 · Cited by 6
Evolution of Coronary Stents: From Birth to Future Trends
Huang, Z., Skarbek, C., Li, Y., Touma, J., Desgranges, P., Gallet, R., & Sénémaud, J. N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010047 · Cited by 7
“Therefore, in the same year, the ESC and AHA began recommending at least 12 months of DAPT for first-generation DES to reduce the risk of LST, although this extended therapy also increased the risk of bleeding [93].”
Kumbhani, D. J., Gibson, C. M., Kinlay, S., Peterson, E. D., Pollak, A. W., Tamis‐Holland, J. E., & Verheugt, F. W. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.037 · Cited by 7
Bonanad, C., Raposeiras‐Roubín, S., García‐Blas, S., Nuñez-Gil, I. J., Vergara-Uzcategui, C. E., Díez‐Villanueva, P., Bañeras, J., Badia-Molins, C., Aboal, J., Carreras‐Mora, J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061680 · Cited by 6
“The DAPT trial, published in 2014, showed a decrease in the composite of death, infarction or stroke, and stent thrombosis in patients who extended DAPT beyond 1 year (up to 30 months) after stent revascularization compared to those who discontinued at 12 months [6].”
BackgroundAntiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope
Jones, D. B., Nicolas, J., Beerkens, F., Satish, M., Feldman, D., Cao, D., Spirito, A., & Mehran, R. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2306207 · Cited by 6
“Historically, prevention of ischemic events and ST elevations took precedence over protection from bleeding, leading to studies exploring DAPT regimens greater than 12 months [4].”
BackgroundRout, A., Sharma, A., Ikram, S., & Garg, A. (2022) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.30521 · Cited by 6
Sex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI
Park, D. Y., Mahajan, S., Fishman, E., Ambrosini, A. P., Acero, L. M. R., Hu, J., Campbell, G., Babapour, G., Kelsey, M. D., Douglas, P. S., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2024.101543 · Cited by 6
Antithrombotic Therapy in People with Hemophilia—A Narrative Review
Nagao, A., Goto, S., & Goto, S. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2548-4192 · Cited by 7
Bhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendra, K., Taha, A., Nadarajah, R., et al. (2025) · Heart · doi:10.1136/heartjnl-2025-326045 · Cited by 7
Immature platelet fraction in cardiology
Cao, Z., & Samarkhazan, H. S. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120600 · Cited by 6
Stent Thrombosis: Current Management and Outcomes
Sommer, P., & Armstrong, E. J. (2015) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-015-0365-2 · Cited by 6
A risk scoring system to predict coronary stent thrombosis
Malik, N., Banning, A. S., Belger, M. A., Fakhouri, W., Graham-Clarke, P., BANNING, A. P., Baumbach, A., Blackman, D. J., de Belder, A., Lefèvre, T., et al. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1292680 · Cited by 6
So, H.-S., So, M.-G., Kang, S.-I., Park, J., Lee, J., Kim, U., & Park, J. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0668 · Cited by 6
“The major findings of the present study: (1) patients in the E-DAPT group had a higher prevalence of LM, 3-vessel, and multivessel diseases and complex PCI; (2) major determinants for E-DAPT were smoking, LM PCI, and complex PCI; (3) although the incidence of MACCE was similar between the G-DAPT and E-DAPT groups, the…”
Result
Metadata
- Authors
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Krucoff, M. W., Hermiller, J., Dauerman, H. L., Simon, D. I., Kandzari, D. E., Garratt, K. N., Lee, D. P., Pow, T. K., Ver Lee, P., Rinaldi, M. J., & Massaro, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Christ Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Missouri–Kansas City (US)
- Duke Medical Center (US)
- St Vincent Hospital (US)
- University of Vermont (US)
- University Hospitals Cleveland Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Lenox Hill Hospital (US)
- Stanford University (US)
- Carolinas Healthcare System (US)
- Boston University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2155-2166
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481318
- OpenAlex
- W2125173296
- Cited by
- 1,928
- References
- 39
- Citations by year
- 2026: 69 · 2025: 75 · 2024: 80 · 2023: 109 · 2022: 125 · 2021: 154 · 2020: 182 · 2019: 150 · 2018: 183 · 2017: 242 · 2016: 288 · 2015: 254 · 2014: 9
- FWCI
- 181.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Food and Drug Administration (1r01fd003870-01, R01 FD003870)
- National Heart, Lung, and Blood Institute (R01HL057506, R37HL057506, K23HL118138)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, drug-eluting stents, coronary stenting, clopidogrel, prasugrel, thienopyridines, aspirin, stent thrombosis, major adverse cardiovascular events, bleeding risk, myocardial infarction, stroke, mortality, periprocedural bleeding, bleeding risk stratification
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Thrombosis, Ticlopidine, Time Factors, Incidence, Myocardial Ischemia, Drug-Eluting Stents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.